Search Results - "EUSEBIO, R. A"

Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid‐Induced Osteoporosis in Men and Women: A Randomized Trial by Reid, David M., Hughes, Rodney A., Laan, Roland F. J. M., Sacco‐Gibson, Nancy A., Wenderoth, Dietrich H., Adami, Silvano, Eusebio, Rachelle A., Devogelaer, Jean‐Pierre

“…Long‐term use of high‐dose corticosteroids often results in bone loss, which may lead to osteoporosis‐related fractures. This was a multicenter, double‐blind…”
Get full text

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data by McClung, M. R., Zanchetta, J. R., Racewicz, A., Roux, C., Benhamou, C.-L., Man, Z., Eusebio, R. A., Beary, J. F., Burgio, D. E., Matzkin, E., Boonen, S., Delmas, P.

“…Summary This study showed that risedronate 150-mg once a month provides similar efficacy and safety at 2 years compared with risedronate 5-mg daily for the…”
Get full text

Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study by Siris, Ethel S., Chines, Arkadi A., Altman, Roy D., Brown, Jacques P., Johnston, C Conrad, Lang, Robert, Mcclung, Michael R., Mallette, Lawrence E., Miller, Paul D., Ryan, Will G., Singer, Frederick R., Tucci, Joseph R., Eusebio, Rachelle A., Bekker, Pirow J.

“…An open‐label, multicenter study was conducted to determine the efficacy and safety of oral risedronate (a pyridinyl bisphosphonate) in 162 patients (102 men,…”
Get full text

Paget’s Disease of Bone: Reduction of Disease Activity With Oral Risedronate by Hosking, D.J, Eusebio, R.A, Chines, A.A

“…Risedronate monosodium [1-hydroxy-2-(3-pyridinyl)ethylidene bisphosphonic acid monosodium salt] is a pyridinyl bisphosphonate drug under development as a…”
Get full text

Improvement of pagetic bone lesions with risedronate treatment: a radiologic study by Brown, J.P, Chines, A.A, Myers, W.R, Eusebio, R.A, Ritter-Hrncirik, C, Hayes, C.W

“…Risedronate is a potent pyridinyl bisphosphonate in clinical development for treatment and prevention of osteoporosis, and has been recently approved for…”
Get full text

Effect of renal function on risedronate pharmacokinetics after a single oral dose by Mitchell, D. Y., St. Peter, J. V., Eusebio, R.A., Pallone, K. A., Kelly, S. C., Russell, D. A., Nesbitt, J. D., Thompson, G. A., Powell, J. H.

“…Aims  To determine the relationship between risedronate pharmacokinetics and renal function. Methods  Risedronate was administered to adult men and women…”
Get full text

Dose-Proportional Pharmacokinetics of Risedronate on Single-Dose Oral Administration to Healthy Volunteers by Mitchell, David Y., Eusebio, Rachelle A., Sacco-Gibson, Nancy A., Pallone, Karen A., Kelly, Sandra C., Nesbitt, John D., Brezovic, Christopher P, Thompson, Gary A., Powefl, James H.

“…Risedronate is a pyridinyl bisphosphonate approved for the treatment of Paget's disease (US‐FDA) and in development for the treatment and prevention of…”
Get full text

Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease by SINGER, F. R, CLEMENS, T. L, EUSEBIO, R. A, BEKKER, P. J

“…Thirteen patients with severe Paget's disease of bone [mean serum alkaline phosphatase (SAP) level 17 times the upper limit of normal] were treated with 30 mg…”
Get full text

Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration by MITCHELL, David Y, BARR, William H, EUSEBIO, Rachelle A, STEVENS, Karen A, DUKE, Frank P, RUSSELL, Darrell A, NESBITT, John D, POWELL, James H, THOMPSON, Gary A

“…To determine the pharmacokinetics and absolute bioavailability of risedronate after single-dose oral administration of 30 mg risedronate as a tablet and an…”
Get full text

Risedronate gastrointestinal absorption is independent of site and rate of administration by MITCHELL, D. Y, EUSEBIO, R. A, DUNLAP, L. E, PALLONE, K. A, NESBITT, J. D, RUSSELL, D. A, CLAY, M. E, BEKKER, P. J

“…Two studies were conducted to compare the absorption of risedronate administered as a solution to three different gastrointestinal sites (study A) and to…”
Get full text

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis by Delmas, Pierre D, McClung, Michael R, Zanchetta, José R, Racewicz, Artur, Roux, Christian, Benhamou, Claude-Laurent, Man, Zulema, Eusebio, Rachelle A, Beary, John F, Burgio, David E, Matzkin, Ellen, Boonen, Steven

“…Abstract Introduction: Risedronate has been shown to be effective in the treatment of postmenopausal osteoporosis when given orally in daily or weekly doses or…”
Get full text

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study by Reid, D M, Hughes, R A, Laan, R F, Sacco-Gibson, N A, Wenderoth, D H, Adami, S, Eusebio, R A, Devogelaer, J P

“…Long-term use of high-dose corticosteroids often results in bone loss, which may lead to osteoporosis-related fractures. This was a multicenter, double-blind…”
Get full text

Risedronate Pharmacokinetics Upon Multiple Dose Oral Administration to Postmenopausal Women for Six Months by Mitchell, D.Y., Thompson, G.A., Eusebio, R.A., Pallone, K.A., Clay, M.E., Russell, D.A., Nesbitt, J.D., Powell, J.H.

“…Clinical Pharmacology & Therapeutics (1999) 65, 189–189; doi:…”
Get full text